Capital Analysts LLC Acquires 6,226 Shares of Zoetis Inc. $ZTS

Capital Analysts LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 8.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 82,034 shares of the company’s stock after buying an additional 6,226 shares during the period. Capital Analysts LLC’s holdings in Zoetis were worth $10,322,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after buying an additional 189,235 shares during the last quarter. Norges Bank bought a new stake in shares of Zoetis in the 4th quarter worth about $734,425,000. Nordea Investment Management AB lifted its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Up 4.1%

Shares of ZTS opened at $82.05 on Wednesday. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $168.83. The company has a 50-day moving average of $99.13 and a 200 day moving average of $115.00. The firm has a market capitalization of $34.40 billion, a price-to-earnings ratio of 13.61, a PEG ratio of 1.23 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ZTS. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Hold” and a consensus target price of $133.92.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received U.K. approval for Lenivia, a long-acting osteoarthritis pain treatment for dogs, which could help expand its companion-animal business and support future product revenue. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Analyst commentary noted Stifel lowered its price target on Zoetis to $95 from $105 while keeping a Hold rating, reinforcing a more cautious near-term view on the stock. Here’s What Analysts Are Saying About Zoetis Inc. (ZTS)
• Negative Sentiment: Multiple law firms announced or reiterated class-action lawsuits and lead-plaintiff deadlines against Zoetis, alleging investor harm tied to alleged securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, which may pressure the shares. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS
• Negative Sentiment: Additional securities-fraud notices from firms including Schall, Gross, Rosen, Glancy Prongay, Levi & Korsinsky, and others keep legal overhang front and center, increasing headline risk for Zoetis. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.